VimRx Pharmaceuticals Inc. said Friday that it has filed for apublic offering of 1,000 units priced at $5,000 per unit. Eachunit will consist of common stock and an identical number ofclass A warrants to purchase common stock. The number ofshares will be determined immediately prior to the offering.D.H. Blair & Co. Inc. is the underwriter.
The stock (NASDAQ:VMRX) closed unchanged Friday at $1.38.
VimRx of Stamford, Conn., is developing drugs based onhypericin, a natural compound derived from St. John's wort, totreat retroviral and viral diseases. The company's first drug,VimRxyn, is in Phase I trials as an AIDS therapeutic.
(c) 1997 American Health Consultants. All rights reserved.